A Study Examining Brentuximab Vedotin in Patients With High-Risk Large B-Cell Lymphoma

Video
Conference|ASH Annual Meeting

Kathryn Kolibaba, MD, associate chair of hematology research program, US Oncology, discusses an ongoing phase 2 study of brentuximab vedotin (Adcetris) with as frontline therapy in patients with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).<br /> &nbsp;

Kathryn Kolibaba, MD, associate chair of hematology research program, US Oncology, discusses an ongoing phase 2 study of brentuximab vedotin (Adcetris) with as frontline therapy in patients with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).

Related Videos
A panel of 3 experts on GVHD
A panel of 3 experts on GVHD
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Stephen T. Oh, MD, PhD, an expert on myelofibrosis
Related Content
Evolving Treatment Paradigms with Amivantamab in Wild-Type NSCLC

Evolving Treatment Paradigms with Amivantamab in Wild-Type NSCLC

April 12th 2024
Article

Natasha Leighl, MD, MMSc, BSc, discussed the analysis of the CHRYSALIS study that was presented at the 2024 American Association for Cancer Research Annual Meeting.

Read More

Examining the Non-Hodgkin Lymphoma Treatment Paradigm

Examining the Non-Hodgkin Lymphoma Treatment Paradigm

July 15th 2022
Podcast

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

Listen

Gene Variant Raises ALL Risk in Hispanic/Latino Children

Gene Variant Raises ALL Risk in Hispanic/Latino Children

April 6th 2024
Article

Adam de Smith, PhD, discussed findings from a study investigating a genetic variant that increases the risk of acute lymphoblastic leukemia in Hispanic/Latino pediatric patients. 

Read More

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

June 15th 2022
Podcast

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

Listen

ChatGPT Scores High for Genetic Counseling in Gynecologic Cancers

ChatGPT Scores High for Genetic Counseling in Gynecologic Cancers

April 3rd 2024
Article

ChatGPT was able to answer general questions about genetic counseling for gynecologic cancers, but some obstacles still remain.

Read More

Comparing Results with Loncastuximab in the Clinic and Real-World Settings in DLBCL

Comparing Results with Loncastuximab in the Clinic and Real-World Settings in DLBCL

April 1st 2024
Article

During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the long-term results with loncastuximab in patients with diffuse large B-cell lymphoma and how this drug fared in the real-world setting in the second article of a 2-part series.

Read More